Slide 1: FY25 Results Investor Briefing
ASX Announcement 22 August 2025 FY25 Results Investor Briefing Cogstate Ltd (ASX:CGS) has today released an Investor Briefing that provides a summary of the financial results for the year ended 30 June 2025 and also provides commentary in respect of the business and financial outlook. For personal u
Slide 2: About Cogstate
About Cogstate Cogstate Ltd (ASX: CGS) is a neuroscience technology company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerised cognitive
Slide 3: Full Year FY2025 Results
For personal use only Full Year FY2025 Results 22nd August 2025 © 2025 Cogstate Ltd. All rights reserved.
Slide 4: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Cogstate Limited (‘Cogstate’). The information in this presentation is of a general nature and does not purport to be complete, nor does it contain all the information which would be required in a prospectus prepared in accordan
Slide 5: Growing Scale, Elevated Market Presence
Growing Scale, Elevated Market Presence For personal use only Proven Leadership in Digital Assessment: Essential CNS Research Partner: Two decades of validated expertise in sensitive, Optimised data collection for all clinical measures in standardised digital cognitive tests, working with top comple
Slide 6: Profitable Growth
Profitable Growth For personal use only Revenue & Profitability, by Financial Year 60 50 Cogstate’s FY2025 is characterised by: 40 US$ Million • Robust growth in clinical trials customer and 61% 30 vendor partner relationships. 58% 56% 20 51% • Expansion into new opportunities in brain 54% health an
Slide 7: FY25 Operational and Financial Highlights
FY25 Operational and Financial Highlights All figures in US$, unless stated For personal use only Revenue Growth Total revenue of $53.1 million, up 22%. Clinical Trials revenue $50.6 million, up 28%. Record Profit Profit before tax $13.9 million, up 96%. NPAT $10.1 million, up 86%. Margin Expansion
Slide 8: FY25 Growth Drivers
FY25 Growth Drivers For personal use only 1 2 3 Business as Usual Sources of Trial Revenue Margin Expansion • Growth in sales contracts • Orexin in sleep disorders • Operating leverage associated delivering strong in-period with revenue growth revenue growth • Continued increase in R&D spend in rare
Slide 9: Capital Allocation
Capital Allocation For personal use only • Maiden fully franked annual dividend of A$0.02 Capital Management Priorities per share for FY25, reflecting confidence in long-term growth and cash generation. • Strategic growth initiatives: Targeting opportunities that align with strategy, enhance • Over
Slide 10: Summary Statement of Group Profit or Loss
Summary Statement of Group Profit or Loss For personal use only US$ millions FY25 FY24 YTY % Revenue 53.1 43.4 22% Gross Profit 32.4 24.6 32% • Revenue growth in Clinical Trials GP% 61% 57% 4% Pts partially offset by decline in Healthcare (see next page for details). Operating Expense (16.5) (15.3)
Slide 11: Summary Statement of Segment Profit or Loss
Summary Statement of Segment Profit or Loss For personal use only Clinical Trials (including Research) Clinical Trials US$ millions FY25 FY24 YTY % • Revenue growth resulting from high in-year revenue yield from improved new contract Revenue 50.6 39.4 28% sales. Direct Costs (excluding depreciation)
Slide 12: Summary Statement of Cash Flow
Summary Statement of Cash Flow For personal use only US$ millions FY25 FY24 YTY % Net Profit after Tax 10.1 5.4 86% Interest Income (0.9) (0.6) 53% Depreciation & Amortization 2.9 2.7 8% • Operating cash flow growth reflects the strength in the Clinical Trials business, Disposal of Assets 0.0 (0.1)
Slide 13: Future Contracted Revenue Run-Off Analysis
Future Contracted Revenue Run-Off For personal use only Analysis 35.0 $35.9m FY26 revenue under contract at 21-Aug-2025 30.0 • $31.5m FY26 revenue under contract as at 30-Jun-2025 o Clinical Trials $29.2m, up 9% YTY (see table) 25.0 o Healthcare $2.3m, consistent with FY25. • $4.4m from new contract
Slide 14: Cogstate Medidata Partnership
Cogstate Medidata Partnership For personal use only Power Smarter Treatments and Healthier People Leading provider of data capture, data analytics and clinical trial management systems Expansion into CNS disease and Cogstate partnership announced October 2024 12
Slide 15: Building Momentum Together – Partnership Highlights
Building Momentum Together – Partnership Highlights For personal use only Shared Wins Integrated Tech & Workflows Joint Go to Market Highlights • Joint sales enablement program, Multiple joint awards in areas of including eBooks, topic guides, fact Long Covid, Parkinson’s Disease, sheets, CNS blogs
Slide 16: Transformative Impact – Cogstate Solutions in Action
Transformative Impact – Cogstate Solutions in Action For personal use only Measuring Brain Impacts of Paediatric Oncology FDA Approval for Alzheimer’s Disease Therapeutic Treatments • Oversaw all aspects of clinical outcome data quality for a successful global • Replaced long and burdensome neurocog
Slide 17: Outlook: Catalysts and Growth Levers for FY26 and Beyond
Outlook: Catalysts and Growth Levers for FY26 and Beyond For personal use only Medidata partnership While FY25 saw pipeline build, FY26 is expected to deliver increased revenue from the Medidata scaling partnership, expanding reach across new CNS indications and customer segments. Commercial launch
Slide 18: FY26 Outlook
FY26 Outlook For personal use only Since 01 July 2025, Cogstate has executed clinical trials sales contracts to the value of $14.1 Strong start to FY26 million, compared to a full year FY25 result of $41.3 million. $35.9 million of contracted FY26 revenue, including $31.5m contracted at 30-Jun-25 an
Slide 19: Cogstate Investor Insights Series – Upcoming Events
Cogstate Investor Insights Series – Upcoming Events For personal use only Annual General Meeting of Shareholders Thursday 16 October 2025 at 11am AEST Virtual and in person – Melbourne Shareholder Day (in-person): Melbourne Friday 7th November 2025 from 8:45am-2.30pm AEDT Registrations Now Open via
Slide 20: A Compelling Investment Proposition
A Compelling Investment Proposition For personal use only Industry-Leading, Critical Partner in Driving Innovation Financial Tech-Driven CNS Clinical in Clinical Profitable Growth: Momentum: Platform: Research: Research: Positioned at the Proven track record, As biopharma Transitioned to strong Reco
Slide 21: For personal use only
For personal use only